Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.
van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R. van Leeuwen FE, et al. Among authors: hagenbeek a. J Natl Cancer Inst. 1995 Oct 18;87(20):1530-7. doi: 10.1093/jnci/87.20.1530. J Natl Cancer Inst. 1995. PMID: 7563187
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R. van Leeuwen FE, et al. Among authors: hagenbeek a. J Clin Oncol. 1994 Feb;12(2):312-25. doi: 10.1200/JCO.1994.12.2.312. J Clin Oncol. 1994. PMID: 8113838
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, Pinedo HM, Somers R. van Leeuwen FE, et al. Among authors: hagenbeek a. J Clin Oncol. 1994 May;12(5):1063-73. doi: 10.1200/JCO.1994.12.5.1063. J Clin Oncol. 1994. PMID: 8164031
Risk of leukemia following treatment for non-Hodgkin's lymphoma.
Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, et al. Travis LB, et al. Among authors: hagenbeek a. J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7. doi: 10.1093/jnci/86.19.1450. J Natl Cancer Inst. 1994. PMID: 8089863
Involved-field radiotherapy for advanced Hodgkin's lymphoma.
Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer Lymphoma Group. Aleman BM, et al. Among authors: hagenbeek a. N Engl J Med. 2003 Jun 12;348(24):2396-406. doi: 10.1056/NEJMoa022628. N Engl J Med. 2003. PMID: 12802025 Free article. Clinical Trial.
Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
Raemaekers J, Burgers M, Henry-Amar M, Pinna A, Mandard A, Monfardini S, Hagenbeek A, Breed W, Carde P, Vovk M, van Hoof A, Thomas J, Noordijk E. Raemaekers J, et al. Among authors: hagenbeek a. Ann Oncol. 1997;8 Suppl 1:111-4. Ann Oncol. 1997. PMID: 9187443 Clinical Trial.
252 results